Palivizumab Antibody
Palivizumab (MEDI-493) is a humanized monoclonal antibody targeting the RSV fusion (F) protein. It neutralizes RSV subtypes A and B by binding to the A antigenic site, preventing viral entry. This antibody is widely used in both in vitro neutralization assays and in vivo models for studying RSV pathogenesis and prophylactic strategies.
Product Specifications
Product Name Alternative
RSV, Synagis, MEDI 493
Target
RSV
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Infectious Disease & Virology
Concentration
4.26 mg/mL
Purity
93.40% (May vary between batches)
Molecular Weight
144.99 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
50469114 3x 1.0 µg
Wsb1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
Sign In for Pricing
View Details MBS2037474-01 0.1 mL
Cy3-Linked Polyclonal Antibody to Monocyte Chemotactic Protein 2 (MCP2)
Sign In for Pricing
View Details MBS2037474-02 0.2 mL
Cy3-Linked Polyclonal Antibody to Monocyte Chemotactic Protein 2 (MCP2)
Sign In for Pricing
View Details MBS2037474-03 0.5 mL
Cy3-Linked Polyclonal Antibody to Monocyte Chemotactic Protein 2 (MCP2)
Sign In for Pricing
View Details MBS2037474-04 1 mL
Cy3-Linked Polyclonal Antibody to Monocyte Chemotactic Protein 2 (MCP2)
Sign In for Pricing
View Details